Savara (NASDAQ:SVRA) Stock Price Down 5.4% – Here’s What Happened

Savara Inc. (NASDAQ:SVRA) shares fell 5.4% during mid-day trading on Friday. The stock traded as low as $4.78 and last traded at $4.7750. 1,487,743 shares were traded during trading, a decline of 11% from the average session volume of 1,662,975 shares. The stock had previously closed at $5.05.

Analyst Ratings Changes

A number of brokerages recently commented on SVRA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Savara Trading Down 5.4%

The business has a 50 day moving average of $5.39 and a 200 day moving average of $5.43. The firm has a market capitalization of $981.07 million, a price-to-earnings ratio of -8.23 and a beta of 0.20. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). As a group, research analysts predict that Savara Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Savara in the second quarter worth $76,966,000. Polar Capital Holdings Plc bought a new stake in shares of Savara in the 4th quarter valued at $50,086,000. Nantahala Capital Management LLC bought a new stake in shares of Savara in the 2nd quarter valued at $42,977,150. Spruce Street Capital LP acquired a new stake in Savara during the 2nd quarter worth $21,267,868. Finally, Pictet Asset Management Holding SA acquired a new stake in Savara during the 1st quarter worth $12,424,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.